Albumin-targeting of an oxaliplatin-releasing platinum(iv) prodrug results in pronounced anticancer activity due to endocytotic drug uptake <i>in vivo</i>.

This overall distribution pattern revealed highly significant increases in the total clearance for KP2157 and oxaliplatin, which were at least one order of magnitude higher than that of KP2156 (Table S1 † ).

also in 132,142 other papers